Evidence map›Paper›PMID 34597599›Full record

ArticleStem cell reports2021

Assessing patient perception of risk in ocular stem cell therapies.

Peter Y Zhao, Sunjong Ji, Paula Anne Newman-Casey, Chris A Andrews, Angeline Lonardi, Olivia M Bennett, Duyhoang Q Dinh, Nidhi Talwar, David W Hutton, Sally Temple and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Peter Y ZhaoDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
Sunjong JiDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
Paula Anne Newman-CaseyDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA; Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
Chris A AndrewsDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
Angeline LonardiDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
Olivia M BennettDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
Duyhoang Q DinhDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
Nidhi TalwarDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA.
David W HuttonInstitute for Health Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Sally TempleDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA; Neural Stem Cell Institute, Rensselaer, NY, USA.
Jeffrey H SternDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA; Neural Stem Cell Institute, Rensselaer, NY, USA.
Rajesh C RaoDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA; Center of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA; Center for RNA Biomedicine, Univeristy of Michigan, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA; A. Alfred Taubman Medical Research Institute, University of Michigan, Ann Arbor, MI, USA; Section of Ophthalmology, Surgery Service, VA Ann Arbor Health System, Ann Arbor, MI, USA. Electronic address: rajeshr@med.umich.edu.
University of Michigan · US

Funding

Molecular Determinants for WDR5-Driven Transcriptional Regulation at Lineage-Specifying Genes During RetinogenesisR01EY030989 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, RAJESH C. · 2020 to 2024
$2.2M
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMDU01EY030581 · NEI · REGENERATIVE RESEARCH FOUNDATION · PI Jeffrey H Stern · 2019 to 2026
$1.7M
Novel Cilia Trafficking MechanismsR01DK084725 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARGOLIS, BENJAMIN L · 2009 to 2010
$702k
Epigenetic Control of Retinal DevelopmentK08EY026654 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, RAJESH C. · 2017 to 2019
$666k
NEI NIH HHS K08 EY026654NEI NIH HHS R01 EY030989NEI NIH HHS U01 EY030581NIDDK NIH HHS R01 DK084725
6 · The paper itself

Abstract

A wide variety of stem cell-derived therapies are under development for the treatment of retinal degeneration. In order to better understand patient perspectives about these therapies, we assessed risk tolerance using an in-person survey of 178 patients at an academic eye center. Risk of malignancy served as a hypothetical, readily understood, and serious adverse event to be considered in trade for potential visual improvement from a stem cell-derived treatment. The results indicate that patients were willing to trade visual improvement against a risk of malignancy that far exceeds actual risk. Two novel findings were that older patients and those with an intermediate level of visual loss were particularly risk tolerant. The quantitative survey results provide a step toward understanding patient perspectives that will, over the long term, guide the development of ocular stem cell-derived therapies.

Indexed as

Patient PreferencePerceptionStem Cell TransplantationAgedAged, 80 and overCell- and Tissue-Based TherapyFemaleHumansMaleMiddle AgedPatientsRetinal DegenerationRisk FactorsSurveys and Questionnairescancercell therapyclinical researchconjoint analysismacular degenerationretinastem cellssurgerysurveytumor

Identifiers

PMID34597599
PMCPMC8514963
OpenAlexW3204002952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.